Peter A. Pinto, MD, presented “Fusion Biopsy Technologies and Techniques” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Pinto, Peter A. “Fusion Biopsy Technologies and Techniques.” November, 2023. Accessed Nov 2024. https://grandroundsinurology.com/fusion-biopsy-technologies-and-techniques/
Fusion Biopsy Technologies and Techniques – Summary
Peter A. Pinto, MD, discusses the evolution of prostate cancer biopsy and imaging techniques in the past twenty years, from blind systematic biopsies to MRI-ultrasound fusion biopsies. He begins by noting that prostate cancer was the only solid-organ tumor diagnosed without image guidance going into the 21st century.
When MRI was introduced as an imaging modality for prostate cancer diagnosis, urologists developed several different techniques for incorporating MRI into biopsy procedures. Dr. Pinto briefly covers the history and development of in-bore biopsies, cognitive fusion biopsies, and MRI-ultrasound fusion biopsies.
He concludes with reviewing the currently available devices in this space. He evaluates each system as it relates to biopsy needle targeting route, tracking and navigation, MRI-ultrasound fusion opportunities, ultrasound image acquisition, and biopsy fixation.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Peter A. Pinto, MD, is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute in Bethesda, Maryland. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Pinto is a board-certified urologic surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.
